Literature DB >> 806246

Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies.

.   

Abstract

Despite the availability of specific antibiotics, Pseudomonas aeruginosa bacteria still cause troublesome infections in patients with a variety of illnesses: extensive thermal injury, leukopenia from antineoplastic chemotherapy and other forms of immunosuppressive treatment, chronic pulmonary disease such as cystic fibrosis, or intravenous narcotic use. The use of antibiotics has improved the prognosis of pseudomonas infections considerably. However, patients with marginal or defective host immunity may need more extensive therapy to master the infection. By evaluating additional modalities of treatment such as granulocyte replacement, improved usage of antibiotics, and active (prophylaxis) or passive antibody administration, the optimal combination may be found.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 806246     DOI: 10.7326/0003-4819-82-6-819

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  42 in total

Review 1.  Chromosomal genetics of Pseudomonas.

Authors:  B W Holloway; V Krishnapillai; A F Morgan
Journal:  Microbiol Rev       Date:  1979-03

2.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

3.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

4.  Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis.

Authors:  S W Hla; K P Hui; W C Tan; B Ho
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Aeration selects for mucoid phenotype of Pseudomonas aeruginosa.

Authors:  D P Krieg; J A Bass; S J Mattingly
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

6.  Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  D P Speert; F Eftekhar; M L Puterman
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

7.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; G J Small; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.

Authors:  J A Hoogkamp-Korstanje; C A Meijer
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

9.  Pseudomonas aeruginosa OspR is an oxidative stress sensing regulator that affects pigment production, antibiotic resistance and dissemination during infection.

Authors:  Lefu Lan; Thomas S Murray; Barbara I Kazmierczak; Chuan He
Journal:  Mol Microbiol       Date:  2009-11-25       Impact factor: 3.501

10.  Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes.

Authors:  J P Pearson; K M Gray; L Passador; K D Tucker; A Eberhard; B H Iglewski; E P Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.